.Veteran venture capital company venBio has actually raised an additional half a billion bucks to acquire biotechs working with health conditions with unmet necessity. The
Read moreiTeos- GSK’s TIGIT star shows significant improvement
.After announcing a stage 3 launch based on favorable midstage end results, iTeos as well as GSK are eventually discussing the highlights coming from the
Read more‘ Professional instinct’ led FDA experts to support Zevra’s unusual illness med
.Zevra Rehabs’ uncommon disease medicine seems to become on the path to authorization this loss after getting the support of an FDA advising board, although
Read moreOtsuka’s renal disease medication strengthens UPCR amounts in ph. 3 trial
.Otsuka Drug’s renal ailment medication has actually hit the primary endpoint of a stage 3 trial through demonstrating in an interim study the decrease of
Read moreBicara, Zenas seek IPOs to drive late-phase resources toward market
.Bicara Therapies and also Zenas Biopharma have actually offered new catalyst to the IPO market along with filings that explain what freshly social biotechs might
Read more‘ All palms on deck’ at Lilly as peers target weight problems market
.Chief executive officer David Ricks can easily observe the business setting up camping tents at basecamp responsible for Eli Lilly in an effort to obtain
Read more8 months after a $213M fundraise, gene publisher Volume creates reduces
.After raising $213 million in 2023– among the year’s biggest personal biotech rounds– Tome Biosciences is helping make cuts.” Even with our clear medical development,
Read more3 biotechs attempt to beat the summer warm by shedding staff
.As biotechs try to turn a fresh page in August, at the very least 3 providers have actually lost team in tries to shape on.
Read more2 cancer cells biotechs combine, producing worldwide impact
.OncoC4 is actually taking AcroImmune– and also its own in-house scientific manufacturing capabilities– under its wing in an all-stock merger.Both cancer biotechs were co-founded through
Read moreZephyrm finds Hong Kong IPO to fund period 3 cell therapy tests
.Zephyrm Bioscience is gusting towards the Hong Kong stock market, filing (PDF) for an IPO to bankroll stage 3 tests of its cell treatment in
Read more